Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis

Journal of Rheumatology

Volumn 37, Issue 11, 2010, Pages 2319-2325

  Kälsch, Anna Isabelle ^a   Csernok, Elena ^b,c   Münch, Dominik ^a   Birck, Rainer ^a   Yard, Benito A ^a   Gross, Wolfgang ^b,c   Kälsch, Thorsten ^a   Schmitt, Wilhelm H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c Klinikum Bad Bramstedt   (Germany)

Author keywords

Antineutrophil cytoplasmic antibodies; C reactive protein; Relapse; Wegener's granulomatosis

Indexed keywords

C REACTIVE PROTEIN; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RELIABILITY; REMISSION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; RECURRENCE; WEGENER GRANULOMATOSIS;

EID: 78149262215     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100302     Document Type: Article

References (26)

1. van der Woude F, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9.
2. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006;47:15-23.
3. Finkielman J, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St. Clair EW, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener's granulomatosis. Ann Intern Med 2007;147:611-9.
4. Nowack R, Grab I, Flores-Suarèz LF, Schnülle P, Yard B, van der Woude FJ. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001;16:1631-7.
5. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42:23-30.
6. Benzaquen LR, Yu H, Rifai N. High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002;39:459-97.
7. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
8. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
9. Honig S, Gorevic P, Weissmann G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 1977;20:1065-70.
10. Hilliquin P. Biological markers in inflammatory rheumatic diseases. Cell Mol Biol 1995;41:993-1006.
11. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, et al. OMERACT 7 Special Interest Group. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005;32:2488-95.
12. Gronhagen-Riska C, Teppo AM, Honkanen E, Ikaheimo R. Alpha-1-antitrypsin, CRP and interleukin-6 in ANCA-positive vasculitis. Adv Exp Med Biol 1993;336:337-40.
13. Hind CR, Winearls CG, Lockwood CM, Rees AJ, Pepys MB. Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol 1984;21:341-5.
14. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995;88:127-33.
15. Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.
16. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14:85-89.
17. Abdou AS, Magour GM, Mahmoud MM. Evaluation of some markers of subclinical atherosclerosis in Egyptian young adult males with abdominal obesity. Br J Biomed Sci 2009;66:143-7.
18. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17:2167-76.
19. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
20. de Maat MP, de Bart AC, Hennis BC, Meijer P, Havelaar AC, Mulder PG, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156-62.
21. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-71.
22. Tervaert JW, Stegeman CA, Kallenberg CG. Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:241-5.
23. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener;s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.
24. Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCA-associated vasculitides. Ann NY Acad Sci 2007;1107:11-21.
25. Woollard KJ, Phillips DC, Griffiths HR. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 2002;130:256-62.
26. Du Clos TW. C-reactive protein as a regulator of autoimmunity and inflammation. Arthritis Rheum 2003;48:1475-7.